Patrick Lynch

Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (38)

Table S6. Gene set enrichment analysis using the KEGG pathways and Gene Ontology Biological Processes databases. Pathways statistically significant activated or suppressed after twelve months exercise are displayed (BH-adjusted P-value

Year:

2025

Table S2. Number of Patients Experiencing Adverse Events by Maximum Grade consent and initiation of exercise regimen (Pre-Study) and in the exercise and usual care group. List with the number of patients experiencing adverse events. Should a patient experience any adverse event, the patient is counted only at the highest (maximum) grade experienced.

Year:

2025

Figure S5. (A) Gene Set Enrichment Analysis (GSEA) of BIOCARTA IL-6 pathway; (B) Gene set of IL-6-stimulated cell cultures; (C) Gene set in IL-6-deprived cell cultures. GSEA was performed by 1000 permutations. The maximum and minimum sizes for gene sets were 500 and 15, respectively. The y-axis represents the enrichment score (ES) and the x-axis lists the ranked genes by fold change. Vertical black lines on the x-axis represent the genes in gene sets. The green line connects points of ES and genes. ES is the maximum deviation from zero as calculated for each gene going down the ranked list and represents the degree of over-representation of a gene set at the top or the bottom of the ranked gene list. The P-value and ES are labeled at the top of the figure. The peak towards to left of the x-axis suggests a positive enrichment of the target gene set and vice versa.

Year:

2025

Table S3. Number of patients experiencing adverse events. Only those toxicities experienced while on the trial are presented in the table. Toxicities during the pre-study stage of the trial, for example, that were present before participants begin intervention were not included. Should a patient experience an adverse event more than once, the patient is only counted once at the highest grade for that adverse event.

Year:

2025

Table S1. Adverse events (AEs) experience by participants with possible or probable relation to the study intervention. Summary of the adverse events by grade, relationship, and arm. Adverse events were reported by subjects, including AEs that happened between consent and initiation of exercise regimen (Pre-Study) and in the exercise and usual care group.

Year:

2025

Figure S4. Relative change in prostaglandin metabolite levels after twelve months follow-up in usual care and exercise groups (A-C, Wilcoxon signed-rank test; ns, P>0.05; *, P ≤0.05; **, P≤0.01).

Year:

2025

Figure S3. (A) Average time that study participants wore the Fitbit throughout the study; (B) Resting heart rate in study participants at baseline; (C) Average total minutes of exercise at heart rate 70-85% of PHR; (D) Average total minutes of exercise at heart rate >85% of PHR. (***, P ≤0.001; ****, P≤0.0001).

Year:

2025

Figure S8. (A) Volcano plot of statistically significant genes and fold-changes between the usual care and exercise groups in DSP assay. Top significantly differentially expressed genes are labeled; (B) The dot plot presents enriched GSEA HALLMARK pathways. The sizes of the dots represent the count of core enrichment (leading-edge) genes. The colors of the dots represent the BH-adjusted P-values. The order of HALLMARK gene sets is based on the gene ratio (number of significant genes associated with the HALLMARK gene sets / total number of significant genes; (C) Total CD8+ T cell density per mm2 (left) and epithelial (right) in colonic mucosa preand post- intervention from usual care (n=4) and exercise (n=4) participants; (D) Total CD57+ NK cell density per mm2 (left) and epithelial (right) in colonic mucosa pre- and post- intervention from usual care (n=4) and exercise (n=4) participants.

Year:

2025

Figure S6. Deconvolution of immune cell types by CIBERSORT. Changes in deconvoluted immune cell type proportions derived from mRNAseq data are shown after twelve months of follow-up in the usual care (N=6) and exercise (N=9) groups using CIBERSORT. No significant changes in immune cell types were observed, though CD8+ T cells were non-statistically significantly higher in the exercise group (two-tail Wilcoxon signed-rank test).

Year:

2025

Butyrate may reduce the risk of colorectal cancer and can be delivered to the colon using butyrylated high-amylose maize starch (HAMSB). This trial evaluated the effects of HAMSB on polyp burden in participants with familial adenomatous polyposis. This study was a randomized, double-blind, placebo-controlled crossover trial. In three 6-month periods, participants ingested 40 g/day of HAMSB or low-amylose starch, followed by the alternative, and then a washout. Participants underwent four video-recorded colonoscopies to assess polyp burden as the primary endpoint. At baseline, two distal bowel tattoos were placed: tattoo one where polyps were cleared at each scope and tattoo two where polyps were left in situ . Generalized linear mixed models were used to estimate the ratio of mean polyp counts in intervention compared with placebo periods. Seventy-two participants were randomized (33 female), with 49 completing the study. In the intention-to-treat analysis, HAMSB did not reduce mean global [0.9 fold change (FC); 95% confidence interval (CI), 0.77–1.06; P = 0.218] or small ( P = 0.267). There was a trend for the reduction of small polyps in tattoo one (0.72 FC; 95% CI, 0.5–1.03; P = 0.074). In the per-protocol analysis, there was a strong trend for HAMSB to reduce mean global small polyp numbers (0.79 FC; 95% CI, 0.62–1; P = 0.051). HAMSB may reduce polyp initiation in the distal bowel without causing regression or growth of existing polyps. However, 95% CIs indicate large uncertainty to the true direction of the treatment effect, and the P values provide only weak evidence against the null hypothesis of no treatment effect. Prevention Relevance: There is convincing evidence that dietary fiber reduces the risk of colorectal cancer possibly by production of butyrate during microbial fermentation of indigestible fiber. This study was designed to determine if a dietary supplement that delivers butyrate to the colon reduces polyp burden in participants with familial adenomatous polyposis.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (22)

Karen Basen-Engquist

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Johannes Fahrmann

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Emma Short

-

UNITED KINGDOM
View details

Melissa Taggart

Associate professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yisheng LI

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Florencia McAllister

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

gareth jenkins

Professor

Swansea University

UNITED KINGDOM
View details

Matthew Mort

Cardiff University

UNITED KINGDOM
View details

Susan C. Gilchrist

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Samir M. Hanash

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

James P. Allison

Professor and Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Eduardo Vilar

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrew Latchford

-

UNITED KINGDOM
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Manoj Chelvanambi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Maartje Nielsen

Clinical geneticist

Leiden University Medical Center

NETHERLANDS
View details

Nicholas Jones

Swansea University

UNITED KINGDOM
View details

Ernest Hawk

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Hannah Deborah West

Senior Lecturer

Cardiff University

UNITED KINGDOM
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christina Dieli-Conwright

Dana-Farber Cancer Institute

UNITED STATES
View details

Laura Thomas

Senior Lecturer

Swansea University

UNITED KINGDOM
View details